2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.
Andre H. Goy, MD, Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology - Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University, Hackensack, NJ, discusses the potential utility of lisocabtagene maraleucel (liso-cel; Breyanzi) in mantle cell lymphoma (MCL).
During the 2020 ASH Annual Meeting and Exposition, findings from the phase 1 TRANSCEND-NHL-001 trial demonstrated an objective response rate of 84% and a complete response rate of 66% with liso-cel in 32 patients with relapsed/refractory MCL.
Moreover, compared with the results of the phase ZUMA-2 trial with brexucabtagene autoleucel (Tecartus), liso-cel appeared to demonstrate fewer cases of grade 3 or higher cytokine release syndrome and neurotoxicity, says Goy.
Although the CAR T-cell therapy is not approved to treat patients with relapsed/refractory MCL, liso-cel could provide another option that leads to durable responses in elderly patients with MCL who would otherwise have limited treatment options, concludes Goy.
Related Content: